Isolation of Human Monoclonal Antibodies That Neutralize Human Rotavirus

Journal of Virology

Volumn 78, Issue 7, 2004, Pages 3325-3332

  Higo Moriguchi, Kyoko ^a   Akahori, Yasushi ^a   Iba, Yoshitaka ^a   Kurosawa, Yoshikazu ^a   Taniguchi, Koki ^a  

^a FUJITA HEALTH UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; CAPSID PROTEIN; EPITOPE; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOGLOBULIN G1; MONOCLONAL ANTIBODY; PROTEIN VP4; PROTEIN VP7; UNCLASSIFIED DRUG; VIRUS ANTIBODY; VIRUS PROTEIN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN HEAVY CHAIN; IMMUNOGLOBULIN LIGHT CHAIN; PEPTIDE LIBRARY; VIRUS ANTIGEN;

AMINO ACID SEQUENCE; ARTICLE; BACULOVIRUS; CROSS REACTION; ENZYME LINKED IMMUNOSORBENT ASSAY; GENOTYPE; HUMAN; MOLECULAR RECOGNITION; NONHUMAN; NUCLEOTIDE SEQUENCE; PHAGE DISPLAY; PRIORITY JOURNAL; PROTEIN BINDING; ROTAVIRUS; SEROTYPE; VIRION; VIRUS NEUTRALIZATION; VIRUS PARTICLE; VIRUS RECOMBINANT; VIRUS STRAIN; ANIMAL; ANTIBODY SPECIFICITY; CHEMISTRY; CLASSIFICATION; DRUG EFFECT; GENETIC REASSORTMENT; GENETICS; IMMUNOLOGY; ISOLATION AND PURIFICATION; MOLECULAR GENETICS; MOUSE; SERODIAGNOSIS; SPECIES DIFFERENCE;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, VIRAL; ANTIBODY SPECIFICITY; ANTIGENS, VIRAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPES; GENOTYPE; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN HEAVY CHAINS; IMMUNOGLOBULIN LIGHT CHAINS; MICE; MOLECULAR SEQUENCE DATA; NEUTRALIZATION TESTS; PEPTIDE LIBRARY; REASSORTANT VIRUSES; ROTAVIRUS; SPECIES SPECIFICITY; VIRAL PROTEINS;

EID: 1842510039     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.78.7.3325-3332.2004     Document Type: Article

References (52)

1. Barbas, C. F., III, E. Bjorling, F. Chiodi, N. Dunlop, D. Cababa, T. M. Jones, S. L. Zebedee, M. A. A. Persson, P. L. Nara, E. Norrby, and D. R. Burton. 1992. Recombinant human Fab fragments neutralize human type 1 immunodeficiency virus in vitro. Proc. Natl. Acad. Sci. USA 89:9339-9343.
2. Barbas, C. F., III, A. S. Kang, R. A. Lerner, and S. J. Benkovic. 1991. Assembly of combinational antibody libraries on phage surfaces: the gene III site. Proc. Natl. Acad. Sci. USA 88:7978-7982.
3. Björling, E., E. von Garrelts, A. Morner, M. Ehnlund, and M. A. A. Persson. 1999. Human neutralizing immunodeficiency virus type 2-specific Fab molecules generated by phage display. J. Gen. Virol. 80:1987-1993.
4. Brunser, O., J. Espinoza, G. Figueroa, M. Araya, E. Spencer, H. Hilpert, H. Link-Amster, and H. Brussow. 1992. Field trial of an infant formula containing anti-rotavirus and anti-Escherichia coli milk antibodies from hyperimmunized cows. J. Pediatr. Gastroenterol. Nutr. 15:63-72.
5. Cale, C. M., and N. J. Klein. 2002. The link between rotavirus vaccination and intussusception: implications for vaccine strategies. Gut 50:11-12.
6. de Carvalho Nicacio, C., Å. Lundkvist, K. B. Sjölander, A. Plyusnin, E. M. Salonen, and E. Björling. 2000. A neutralizing recombinant human antibody Fab fragment against Puumala hantavirus. J. Med. Virol. 60:446-454.
7. de Carvalho Nicacio, C., R. A. Williamson, P. W. H. I. Parren, Å. Lundkvist, D. R. Burton, and E. Björling. 2002. Neutralizing human Fab fragments against measles virus recovered by phage display. J. Virol. 76:251-258.
8. Desselberger, U., M. Iturriza-Gómara, and J. J. Gray. 2000. Rotavorus epidemiology and surveillance. Novartis Found. Symp. 238:125-152.
9. Ebina, T., A. Sato, K. Umezu, N. Ishida, S. Ohyama, A. Ohizumi, K. Aikawa, S. Katagiri, N. Katsushima, and A. Imai. 1983. Prevention of rotavirus infection by cow colostrum antibody against human rotaviruses. Lancet ii:1029-1030.
10. Ebina, T., A. Sato, K. Umezu, N. Ishida, S. Ohyama, A. Oizumi, K. Aikawa, S. Katagiri, N. Katsushima, and A. Imai. 1985. Prevention of rotavirus infection by oral administration of cow colostrum containing anti-human rotavirus antibody. Med. Microbiol. Immunol. 174:177-185.
11. Estes, M. K. 2001. Rotaviruses and their replication, p. 1747-1786. In D. M. Knipe and P. M. Howley (ed.), Fields virology, 4th ed. Lippincott/The Williams & Wilkins Co., Philadelphia, Pa.
12. Gilger, M. A., D. O. Matson, M. E. Conner, H. M. Rosenblatt, M. J. Finegold, and M. K. Estes. 1992. Extraintestinal rotavirus infections in children with immunodeficiency. J. Pediatr. 120:912-917.
13. Green, K. Y., K. Taniguchi, E. R. Mackow, and A. Z. Kapikian. 1990. Homotypic and heterotypic epitope-specific antibody responses in adult and infant rotavirus vaccines: implications for vaccine development. J. Infect. Dis. 161:667-679.
14. Greenberg, H. B., J. Valdesuso, K. van Wyke, K. Midthun, M. Walsh, V. McAuliffe, R. G. Wyatt, A. R. Kalica, J. Flores, and Y. Hoshino. 1983. Production and preliminary characterization of monoclonal antibodies directed at two surface proteins of rhesus rotavirus. J. Virol. 47:267-275.
15. Guarino, A., R. B. Canani, S. Russo, F. Albano, M. B. Canani, F. M. Ruggeri, G. Donelli, and A. Rubino. 1994. Oral immunoglobulins for treatment of acute rotaviral gastroenteritis. Pediatrics 93:12-16.
16. Guarino, A., S. Russo, A. Castaldo, M. I. Spagnuolo, L. Tarallo, and A. Rubino. 1996. Passive immunotherapy for rotavirus-induced diarrhoea in children with HIV infection. AIDS 10:1176-1178.
17. Hammarström, L. 1999. Passive immunity against rotavirus in infants. Acta Pediatr. Suppl. 430:127-132.
18. Hoshino, Y., L. J. Saif, M. M. Sereno, R. M. Chanock, and A. Z. Kapikian. 1988. Infection immunity of piglets to either VP3 or VP7 outer capsid protein confers resistance to challenge with a virulent rotavirus bearing the corresponding antigen. J. Virol. 62:744-748.
19. Hoshino, Y., M. M. Sereno, K. Midthun, J. Flores, A. Z. Kapikian, and R. M. Chanock. 1985. Independent segregation of two antigenic specificities (VP3 and VP7) involved in neutralization of rotavirus infectivity. Proc. Natl. Acad. Sci. USA 82:8701-8704.
20. Iba, Y., W. Ito, and Y. Kurosawa. 1997. Expression vectors for the introduction of highly diverged sequences into the six complementarity-determining regions of an antibody. Gene 194:35-46.
21. Ichihara, Y., H. Matsuoka, and Y. Kurosawa. 1988. Organization of human immunoglobulin heavy chain diversity gene loci. EMBO J. 7:4141-4150.
22. Ito, W., and Y. Kurosawa. 1993. Development of an artificial antibody system with multiple valency using an Fv fragment fused to a fragment of protein A. J. Biol. Chem. 268:20668-20675.
23. Kabat, E. A., T. T. Wu, H. M. Perry, K. S. Gottesman, and C. Foeller. 1991. Sequences of proteins of immunological interest. National Institutes of Health, Bethesda, Md.
24. Kapikian, A. Z., Y. Hoshino, and R. M. Chanock. 2001. Rotaviruses, p. 1787-1833. In D. M. Knipe and P. M. Howley (ed.), Fields virology, 4th ed. Lippincott/The Williams & Wilkins Co., Philadelphia, Pa.
25. Kapikian, A. Z., Y. Hoshino, R. M. Chanock, and I. Pérez-Schael. 1996. Efficacy of a quadrivalent rhesus rotavirus-based human rotavirus vaccine aimed at preventing severe rotavirus diarrhea in infants and young children. J. Infect. Dis. 174(Suppl. 1):S65-S72.
26. Kobayashi, N., K. Taniguchi, and S. Urasawa. 1990. Identification of operationally overlapping and independent cross-reactive neutralization regions on human rotavirus VP4. J. Gen. Virol. 71:2615-2623.
27. Marks, J. D., H. R. Hoogenboom, T. P. Bonnert, J. McCafferty, A. D. Griffiths, and G. Winter. 1991. By-passing immunization. Human antibodies from V-gene libraries displayed on phage. J. Mol. Biol. 222:581-597.
28. Maruyama, T., L. L. Rodroguez, P. B. Jahring, A. Sanchez, A. S. Khan, S. T. Nichol, C. J. Peters, P. W. H. I. Parren, and D. R. Burton. 1999. Ebola virus can be effectively neutralized by antibody produced in natural human infection. J. Virol. 73:6024-6030.
29. Matsui, S. M., E. R. Mackow, and H. B. Greenberg. 1989. Molecular determinant of rotavirus neutralization and protection. Adv. Virus Res. 36:181-214.
30. Matsui, S. M., P. A. Offit, P. T. Vo, E. R. Mackow, D. A. Benfield, R. D. Shaw, L. Padilla-Noriega, and H. B. Greenberg. 1989. Passive protection against rotavirus-induced diarrhea by monoclonal antibodies to the heterotypic neutralization domain of VP7 and the VP8 fragment of VP4. J. Clin. Microbiol. 27:780-782.
31. McCafferty, J., A. D. Griffiths, G. Winter, and D. J. Chiswell. 1990. Phage antibodies: filamentous phage displaying antibody variable domains. Nature 348:552-554.
32. Midthun, K., Y. Hoshino, A. Z. Kapikian, and R. M. Chanock. 1986. Single gene substitution rotavirus reassortants containing the major neutralization protein (VP7) of human rotavirus serotype 4. J. Clin. Microbiol. 24:822-826.
33. Miller, M. A., and L. McCann. 2000. Policy analysis of the use of hepatitis B, Haemophilus influenzae type B-, Streptococcus pneumoniae-conjugate, and rotavirus vaccines in national immunization schedules. Health Econ. 9:19-35.
34. Mori, I., K. Matsumoto, K. Sugimoto, M. Kimura, N. Daimon, T. Yokochi, and Y. Kimura. 2002. Prolonged shedding of rotavirus in a geriatric inpatient. J. Med. Virol. 67:613-615.
35. Morino, K., H. Katsumi, Y. Akahori, Y. Iba, M. Shinohara, Y. Ukai, Y. Kohara, and Y. Kurosawa. 2001. Antibody fusions with fluorescent proteins: a versatile reagent for profiling protein expression. J. Immunol. Methods 257:175-184.
36. Morita, Y., K. Taniguchi, T. Urasawa, and S. Urasawa. 1988. Analysis of serotype-specific neutralization epitopes on VP7 of human rotavirus by the use of neutralizing monoclonal antibodies and antigenic variants. J. Gen. Virol. 69:451-458.
37. Moulard, M., S. K. Phogat, Y. Shu, A. F. Labrijn, X. Xiao, J. M. Binley, M. Zhang, I. A. Sidorov, C. C. Broder, J. Robinson, P. W. H. I. Parren, D. R. Burton, and D. S. Dimitrov. 2002. Broadly cross-reactive HIV-1-neutralizing human monoclonal Fab selected for binding to gp120-CD4-CCR5 complexes. Proc. Natl. Acad. Sci. USA 99:6913-6918.
38. Murphy, T. V., P. M. Gargiullo, M. S. Massoudi, D. B. Nelson, A. O. Jumaan, C. A. Okoro, L. R. Zanardi, S. Setia, E. Fair, C. W. LeBaron, M. Wharton, and J. R. Livingood. 2001. For the rotavirus intussusception investigation team: intussusception among infants given an oral rotavirus vaccine. N. Engl. J. Med. 344:564-572.
39. Nakajima, H., T. Nakagomi, T. Kamisawa, N. Sakaki, K. Muramoto, T. Mikami, H. Nara, and O. Nakagomi. 2001. Winter seasonality and rotavirus diarrhoea in adults. Lancet 357:1950.
40. Offit, P. A. 1996. Host factors associated with protection against rotavirus disease: the skies are clearing. J. Infect. Dis. 174(Suppl. 1):S59-S64.
41. Offit, P. A., R. D. Shaw, and H. B. Greenberg. 1986. Passive protection against rotavirus-induced diarrhea by monoclonal antibodies to surface proteins VP3 and VP7. J. Virol. 58:700-703.
42. Pedley, S., F. Hundley, I. Chrystie, M. A. McCrae, and U. Desselberger. 1984. The genomes of rotaviruses isolated from chronically infected immunodeficient children. J. Gen. Virol. 65:1141-1150.
43. Peigue-Lafeuille, H., C. Henquell, M. Chambon, N. Gazuy, C. De Champs, and R. Cluzel. 1991. Nosocomial rotavirus infections in adult renal transplant recipients. J. Hosp. Infect. 18:67-70.
44. Sheets, M. D., P. Amersdorfer, R. Finnern, P. Sargent, E. Lindquist, R. Schier, G. Hemingsen, C. Wong, J. C. Gerhart, and J. D. Marks. 1998. Efficient construction of a large nonimmune phage antibody library: the production of high-affinity human single-chain antibodies to protein antigens. Proc. Natl. Acad. Sci. USA 95:6157-6162.
45. Taniguchi, K., Y. Hoshino, K. Nishikawa, K. Y. Green, W. L. Maloy, Y. Morita, S. Urasawa, A. Z. Kapikian, R. M. Chanock, and M. Gorziglia. 1988. Cross-reactive and serotype-specific neutralization epitopes on VP7 of human rotavirus: nucleotide sequence analysis of antigenic mutants selected with monoclonal antibodies. J. Virol. 62:1870-1874.
46. Taniguchi, K., W. L. Maloy, K. Nishikawa, K. Y. Green, Y. Hoshino, S. Urasawa, A. Z. Kapikian, R. M. Chanock, and M. Gorziglia. 1988. Identification of cross-reactive and serotype 2-specific neutralization epitopes on VP3 of human rotavirus. J. Virol. 62:2421-2426.
47. Taniguchi, K., Y. Morita, T. Urasawa, and S. Urasawa. 1987. Cross-reactive neutralization epitopes on VP3 of human rotavirus: analysis with monoclonal antibodies and antigenic variants. J. Virol. 61:1726-1730.
48. Taniguchi, K., T. Urasawa, N. Kobayashi, M. U. Ahmed, N. Adachi, S. Chiba, and S. Urasawa. 1991. Antibody response to serotype-specific and cross-reactive neutralization epitopes on VP4 and VP7 after rotavirus infection or vaccination. J. Clin. Microbiol. 29:483-487.
49. Taniguchi, K., S. Urasawa, and T. Urasawa. 1985. Preparation and characterization of neutralizing monoclonal antibodies with different reactivity patterns to human rotaviruses. J. Gen. Virol. 66:1045-1053.
50. Tsui, P., M. A. Tornetta, R. S. Ames, B. C. Bankosky, S. Griego, C. Silverman, T. Porter, G. Moore, and R. W. Sweet. 1996. Isolation of a neutralizing human RSV antibody from a dominant, non-neutralizing immune repertoire by epitope-blocked panning. J. Immunol. 157:772-780.
51. Ward, R. L., D. R. Knowlton, G. M. Schiff, Y. Hoshino, and H. B. Greenberg. 1988. Relative concentrations of serum neutralizing antibody to VP3 and VP7 proteins in adults infected with a human rotavirus. J. Virol. 62:1543-1549.
52. Winter, G., A. D. Griffiths, R. E. Hawkins, and H. R. Hoogenboom. 1994. Making antibodies by phage display technology. Annu. Rev. Immunol. 12:433-455.